Many GPCRs are predominately found in the brain or the CNS, and, therefore, we believe targeting GPCRs provides an opportunity to selectively treat various CNS diseases. Many approved drugs for indications ranging from insomnia and narcolepsy to depression, schizophrenia and Parkinson's disease target GPCRs. Our discovery efforts in CNS diseases are focused on indications with large market opportunities where current therapies have significant limitations.

(This page was last updated: June 5, 2008. Additional information regarding Arena is available in its SEC filings.)